What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

September 30, 2025Frontiers in ImmunologyOpen Access

CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

YHYing He LQLing Qiu DCDan Chen

Discussion

Member takes

Overview

Literature review reveals CAR T-cell therapy offers higher response rates and longer survival in relapsed follicular lymphoma patients, suggesting improved outcomes.

Key Points

CAR T-cell therapy showed superior overall response rates of 92% versus bispecific antibodies at 77%, and a longer median progression-free survival of 15 months compared to 9 months.
Adverse events were more frequent with CAR T-cell therapy, particularly neurotoxicity, which occurred in 7% of patients, but most were grade 1–2 in severity.
The analysis included 12 studies involving 1,200 patients, reflecting a comprehensive review of current therapeutic approaches for relapsed/refractory follicular lymphoma.
Findings highlight that while CAR T-cell therapy indicates improved efficacy, its associated adverse events must be carefully managed in clinical practice.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68dc262a8a7d58c25ebb3439 https://doi.org/10.3389/fimmu.2025.1611984

View Full Paper

Ask AI

Bookmark

September 30, 2025Frontiers in ImmunologyOpen Access

CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

YHYing He LQLing Qiu DCDan Chen

Discussion

Member takes

Overview

Literature review reveals CAR T-cell therapy offers higher response rates and longer survival in relapsed follicular lymphoma patients, suggesting improved outcomes.

Key Points

CAR T-cell therapy showed superior overall response rates of 92% versus bispecific antibodies at 77%, and a longer median progression-free survival of 15 months compared to 9 months.
Adverse events were more frequent with CAR T-cell therapy, particularly neurotoxicity, which occurred in 7% of patients, but most were grade 1–2 in severity.
The analysis included 12 studies involving 1,200 patients, reflecting a comprehensive review of current therapeutic approaches for relapsed/refractory follicular lymphoma.
Findings highlight that while CAR T-cell therapy indicates improved efficacy, its associated adverse events must be carefully managed in clinical practice.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68dc262a8a7d58c25ebb3439 https://doi.org/10.3389/fimmu.2025.1611984

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark